▲ +65.19% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $55.80, with a high forecast of $80.00 and a low forecast of $37.00. The average price target represents a 65.19% upside from the last price of $33.78.
The current consensus among 5 contributing investment analysts is to hold stock in Prelude Therapeutics.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.